PNC Financial Services Group
SYRE icon

PNC Financial Services Group’s Spyre Therapeutics SYRE Stock Holding History

PNC Financial Services Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.2K Buy
123
+37
+43% +$1.4K ﹤0.01% 4164
2025
Q4 		$2.82K Hold
86
– – ﹤0.01% 4439
2025
Q3 		$1.44K Buy
+86
New +$1.4K ﹤0.01% 4585

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

PNC Financial Services Group's SYRE Position: Q1 2026 in Review

PNC Financial Services Group increased its Spyre Therapeutics (SYRE) stake by 43% in Q1 2026, buying an estimated $1.4K and bringing the position to 123 shares worth $6.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4164.

PNC Financial Services Group first reported a position in SYRE in Q3 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • PNC Financial Services Group held 123 shares of Spyre Therapeutics worth $6.2K as of Q1 2026.
  • PNC Financial Services Group bought 37 Spyre Therapeutics shares in Q1 2026, an estimated $1.4K.
  • Spyre Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4164 holding.
  • PNC Financial Services Group first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.